PMID- 20390388
OWN - NLM
STAT- MEDLINE
DCOM- 20100813
LR  - 20211020
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 91
IP  - 4
DP  - 2010 May
TI  - Haploidentical hematopoietic stem cell transplantation to adults with hematologic 
      malignancies: analysis of 66 cases at a single Japanese center.
PG  - 661-9
LID - 10.1007/s12185-010-0561-5 [doi]
AB  - Sixty-six adult patients with hematologic malignancies underwent haploidentical 
      hematopoietic stem cell transplantation (haplo-HSCT) without T cell depletion. 
      The patients were preconditioned with a reduced intensity regimen, and tacrolimus 
      was used for graft-versus-host disease (GVHD) prophylaxis. Successful engraftment 
      occurred in 60 patients (90.1%) and graft rejection in only 4 patients (6.1%). 
      Among the 60 engrafted patients, only 5 developed severe (grade III or IV) acute 
      GVHD. Twenty patients, including 19 relapse-free patients were alive at a median 
      follow-up of 48 months (range 6-77 months). The overall survival (OS) at 6 years 
      was 29.3%. The OS of 45 patients < 60 years of age was 43.6%, which was superior 
      to that of 21 patients who were 60 years of age and older (9.5%) (P < 0.01). The 
      OS of 11 patients from human leukocyte antigen (HLA) 1 locus-mismatched donors 
      (63.6%) was higher than that of 28 patients from HLA 3 loci-mismatched donors 
      (12.5%) (P < 0.01). Organ injury and infection were the main causes of mortality. 
      Notably, immunosuppressive therapy could be successfully stopped in 9 patients 
      transplanted from HLA 2 or 3 loci-mismatched donors with a median duration of 45 
      months (range 5-71 months). These data suggest that haplo-HSCT is a promising 
      treatment for patients who need urgent allogeneic transplantation but lack 
      HLA-identical family donors.
FAU - Kurokawa, Toshiro
AU  - Kurokawa T
AD  - Department of Internal Medicine, Toyama Prefectural Central Hospital, Nishinagae, 
      Toyama, Japan. kurokawa@tch.pref.toyama.jp
FAU - Ishiyama, Ken
AU  - Ishiyama K
FAU - Ozaki, Jun
AU  - Ozaki J
FAU - Yamashita, Yumiko
AU  - Yamashita Y
FAU - Iwaki, Noriko
AU  - Iwaki N
FAU - Saito, Chizuru
AU  - Saito C
FAU - Arahata, Masahisa
AU  - Arahata M
FAU - Kaya, Hiroyasu
AU  - Kaya H
FAU - Yoshida, Takashi
AU  - Yoshida T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Immunosuppressive Agents)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cytomegalovirus Infections/mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Rejection/drug therapy/mortality
MH  - Graft vs Host Disease/drug therapy/mortality
MH  - *Haplotypes
MH  - *Hematologic Neoplasms/genetics/mortality/therapy
MH  - Hematopoietic Stem Cell Transplantation/*methods/*mortality
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Japan/epidemiology
MH  - Lymphocyte Count
MH  - Lymphocyte Subsets/cytology
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Survival Analysis
MH  - Tacrolimus/therapeutic use
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2010/04/15 06:00
MHDA- 2010/08/14 06:00
CRDT- 2010/04/15 06:00
PHST- 2010/01/22 00:00 [received]
PHST- 2010/03/18 00:00 [accepted]
PHST- 2010/03/12 00:00 [revised]
PHST- 2010/04/15 06:00 [entrez]
PHST- 2010/04/15 06:00 [pubmed]
PHST- 2010/08/14 06:00 [medline]
AID - 10.1007/s12185-010-0561-5 [doi]
PST - ppublish
SO  - Int J Hematol. 2010 May;91(4):661-9. doi: 10.1007/s12185-010-0561-5.